Abstract:

ABSTRACT: Calcineurin inhibitor (CNI) is a mainstay of immunosuppressant agents for most solid organ transplant patients. Tacrolimus, which is widely used, has a narrow therapeutic range and its pharmacokinetic variability complicates its daily dose assessment. One of tacrolimus’ major side effect is nephrotoxicity. Several genes involve in the metabolism of tacrolimus, but whether the genetically polymorphisms play a role in tacrolimus’ chronic nephrotoxicity remains unknown

Key words: tacrolimus, nephrotoxicity, gene